865 related articles for article (PubMed ID: 22054881)
21. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression.
Selamat SA; Chung BS; Girard L; Zhang W; Zhang Y; Campan M; Siegmund KD; Koss MN; Hagen JA; Lam WL; Lam S; Gazdar AF; Laird-Offringa IA
Genome Res; 2012 Jul; 22(7):1197-211. PubMed ID: 22613842
[TBL] [Abstract][Full Text] [Related]
22. Clinical relevance of molecular markers in lung cancer.
Iyengar P; Tsao MS
Surg Oncol; 2002 Dec; 11(4):167-79. PubMed ID: 12450553
[TBL] [Abstract][Full Text] [Related]
23. Molecular pathogenesis of lung cancer and potential translational applications.
Minna JD; Fong K; Zöchbauer-Müller S; Gazdar AF
Cancer J; 2002; 8 Suppl 1():S41-6. PubMed ID: 12075701
[TBL] [Abstract][Full Text] [Related]
24. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering.
Girard L; Zöchbauer-Müller S; Virmani AK; Gazdar AF; Minna JD
Cancer Res; 2000 Sep; 60(17):4894-906. PubMed ID: 10987304
[TBL] [Abstract][Full Text] [Related]
25. Role of chromosome 3q amplification in lung cancer.
Qian J; Massion PP
J Thorac Oncol; 2008 Mar; 3(3):212-5. PubMed ID: 18317062
[TBL] [Abstract][Full Text] [Related]
26. Molecular and genetic changes in asbestos-related lung cancer.
Nymark P; Wikman H; Hienonen-Kempas T; Anttila S
Cancer Lett; 2008 Jun; 265(1):1-15. PubMed ID: 18364247
[TBL] [Abstract][Full Text] [Related]
27. Heterogeneity in Lung Cancer.
de Sousa VML; Carvalho L
Pathobiology; 2018; 85(1-2):96-107. PubMed ID: 29635240
[TBL] [Abstract][Full Text] [Related]
28. Challenges of deciphering gastric cancer heterogeneity.
Hudler P
World J Gastroenterol; 2015 Oct; 21(37):10510-27. PubMed ID: 26457012
[TBL] [Abstract][Full Text] [Related]
29. [Molecular-genetic markers in lung cancer diagnostics].
Ponomareva AA; Rykova EIu; Cherdyntseva NV; Choĭnzonov EL; Laktionov PP; Vlasov VV
Mol Biol (Mosk); 2011; 45(2):203-17. PubMed ID: 21634110
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic Biomarkers for Risk Assessment of Particulate Matter Associated Lung Cancer.
Bhargava A; Bunkar N; Aglawe A; Pandey KC; Tiwari R; Chaudhury K; Goryacheva IY; Mishra PK
Curr Drug Targets; 2018; 19(10):1127-1147. PubMed ID: 28891455
[TBL] [Abstract][Full Text] [Related]
31. DNA methylation patterns in lung carcinomas.
Pfeifer GP; Rauch TA
Semin Cancer Biol; 2009 Jun; 19(3):181-7. PubMed ID: 19429482
[TBL] [Abstract][Full Text] [Related]
32. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies.
Shames DS; Girard L; Gao B; Sato M; Lewis CM; Shivapurkar N; Jiang A; Perou CM; Kim YH; Pollack JR; Fong KM; Lam CL; Wong M; Shyr Y; Nanda R; Olopade OI; Gerald W; Euhus DM; Shay JW; Gazdar AF; Minna JD
PLoS Med; 2006 Dec; 3(12):e486. PubMed ID: 17194187
[TBL] [Abstract][Full Text] [Related]
33. Expression of the DMBT1 gene is frequently suppressed in human lung cancer.
Takeshita H; Sato M; Shiwaku HO; Semba S; Sakurada A; Hoshi M; Hayashi Y; Tagawa Y; Ayabe H; Horii A
Jpn J Cancer Res; 1999 Sep; 90(9):903-8. PubMed ID: 10551316
[TBL] [Abstract][Full Text] [Related]
34. Genomic aberrations in lung adenocarcinoma in never smokers.
Job B; Bernheim A; Beau-Faller M; Camilleri-Broët S; Girard P; Hofman P; Mazières J; Toujani S; Lacroix L; Laffaire J; Dessen P; Fouret P;
PLoS One; 2010 Dec; 5(12):e15145. PubMed ID: 21151896
[TBL] [Abstract][Full Text] [Related]
35. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints.
Wistuba II; Behrens C; Virmani AK; Mele G; Milchgrub S; Girard L; Fondon JW; Garner HR; McKay B; Latif F; Lerman MI; Lam S; Gazdar AF; Minna JD
Cancer Res; 2000 Apr; 60(7):1949-60. PubMed ID: 10766185
[TBL] [Abstract][Full Text] [Related]
36. The Roles of MicroRNA in Lung Cancer.
Wu KL; Tsai YM; Lien CT; Kuo PL; Hung AJ
Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30935143
[TBL] [Abstract][Full Text] [Related]
37. EGFR activating aberration occurs independently of other genetic aberrations or telomerase activation in adenocarcinoma of the lung.
Arifin M; Hiyama K; Tanimoto K; Wiyono WH; Hiyama E; Nishiyama M
Oncol Rep; 2007 Jun; 17(6):1405-11. PubMed ID: 17487398
[TBL] [Abstract][Full Text] [Related]
38. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.
Chen Z; Cheng K; Walton Z; Wang Y; Ebi H; Shimamura T; Liu Y; Tupper T; Ouyang J; Li J; Gao P; Woo MS; Xu C; Yanagita M; Altabef A; Wang S; Lee C; Nakada Y; Peña CG; Sun Y; Franchetti Y; Yao C; Saur A; Cameron MD; Nishino M; Hayes DN; Wilkerson MD; Roberts PJ; Lee CB; Bardeesy N; Butaney M; Chirieac LR; Costa DB; Jackman D; Sharpless NE; Castrillon DH; Demetri GD; Jänne PA; Pandolfi PP; Cantley LC; Kung AL; Engelman JA; Wong KK
Nature; 2012 Mar; 483(7391):613-7. PubMed ID: 22425996
[TBL] [Abstract][Full Text] [Related]
39. Molecular origins of lung cancer: prospects for personalized prevention and therapy.
Haura EB; Camidge DR; Reckamp K; Chiappori A; Johnson F; Herbst R; Wong K; Carbone D
J Thorac Oncol; 2010 Jun; 5(6 Suppl 3):S207-13. PubMed ID: 20502275
[TBL] [Abstract][Full Text] [Related]
40. Intracellular signals of lung cancer cells as possible therapeutic targets.
Tanaka K; Kumano K; Ueno H
Cancer Sci; 2015 May; 106(5):489-96. PubMed ID: 25707772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
